MSH3 and cancer: Given the lack of evidence for mutation and epigenic inactivation, the defect for MSH3 to cause EMAST had to be an acquired trait for the cancer, and commensurate with this idea is the increased prevalence of EMAST along the adenoma-to-carcinoma continuum.